Cancer

Title
A Study of the Effects of Gemcitabine given by Itself Versus Gemcitabine Combined with the Study Drug Pazopanib in Soft-Tissue Sarcoma
Trial Number
205478061913
Number of Participants
80
Principal Investigator

Janelle Meyer

M.D.
Hematology/Oncology
Assistant Professor
Category
Cancer: Bone
Eligibility

Patients eligible for this study will be 18 or older; have measureable metastatic or unresectable soft-tissue sarcoma; good performance status; have received at least one, but not more than three, systemic regimens for treatment of this disease, one of which must have been anthracycline-based; and have adequate organ system function.

Purpose

This study is being done to compare the effects, good and/or bad, between gemcitabine given by itself to gemcitabine combined with the study drug pazopanib.

Enrollment

(708) 327-3180

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.